Neratinib for the treatment of HER2-positive early stage breast cancer.

Richat Abbas, Bruce A. Hug, Cathie Leister, Jaime Burns, Daryl Sonnichsen, Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects British Journal of Clinical Pharmacology. ,vol. 71, pp. 522- 527 ,(2011) , 10.1111/J.1365-2125.2010.03845.X

Devika Gajria, Shanu Modi, Cristina Saura, Rita Sakr, Karl Solano, Helen Won, Harpreet Pannu, Sujata Patil, Diana Lake, Tiffany Traina, Tari King, Michael Berger, Jose Baselga, Neal Rosen, Cliff Hudis, Sarat Chandarlapaty, Abstract P5-19-04: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-P5-19-04

Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A O’Brien, Ioannis Roxanis, Ji-Liang Li, Esther Bridge, Richard Finn, Dennis Slamon, Patricia McGowan, Michael J. Duffy, Norma O’Donovan, John Crown, Anthony Kong, Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. ,vol. 4, pp. 1592- 1605 ,(2013) , 10.18632/ONCOTARGET.1148

Rita Nahta, Francisco J Esteva, HER2 therapy: Molecular mechanisms of trastuzumab resistance Breast Cancer Research. ,vol. 8, pp. 215- 215 ,(2006) , 10.1186/BCR1612

Anthony Kong, Katharina Feldinger, Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer. ,vol. 7, pp. 147- 162 ,(2015) , 10.2147/BCTT.S54414

Miguel Martin, Jacques Bonneterre, Charles E. Geyer, Yoshinori Ito, Jungsil Ro, Istvan Lang, Sung-Bae Kim, Caroline Germa, Jennifer Vermette, Kenneth Wang, Kongming Wang, Ahmad Awada, A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer European Journal of Cancer. ,vol. 49, pp. 3763- 3772 ,(2013) , 10.1016/J.EJCA.2013.07.142

Attila A. Seyhan, Usha Varadarajan, Sung Choe, Wei Liu, Terence E. Ryan, A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers Molecular BioSystems. ,vol. 8, pp. 1553- 1570 ,(2012) , 10.1039/C2MB05512K

Rachel C Jankowitz, Jame Abraham, Antoinette R Tan, Steven A Limentani, Marni B Tierno, Laura M Adamson, Marc Buyse, Norman Wolmark, Samuel A Jacobs, None, Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemotherapy and Pharmacology. ,vol. 72, pp. 1205- 1212 ,(2013) , 10.1007/S00280-013-2262-2

Ami Citri, Yosef Yarden, EGF–ERBB signalling: towards the systems level Nature Reviews Molecular Cell Biology. ,vol. 7, pp. 505- 516 ,(2006) , 10.1038/NRM1962

Aron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, Evandro de Azambuja, Marion Procter, Thomas M Suter, Christian Jackisch, David Cameron, Harald A Weber, Dominik Heinzmann, Lissandra Dal Lago, Eleanor McFadden, Mitch Dowsett, Michael Untch, Luca Gianni, Richard Bell, Claus-Henning Köhne, Anita Vindevoghel, Michael Andersson, A Murray Brunt, Douglas Otero-Reyes, Santai Song, Ian Smith, Brian Leyland-Jones, Jose Baselga, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial The Lancet. ,vol. 382, pp. 1021- 1028 ,(2013) , 10.1016/S0140-6736(13)61094-6